Steroid Corticosteroids Sales

Steroid Corticosteroids Sales Market Outlook

The global Steroid Corticosteroids market is projected to reach approximately USD 8.5 billion by 2035, growing at a compound annual growth rate (CAGR) of about 5.8% from 2025 to 2035. This growth can be attributed to the increasing prevalence of chronic conditions that require corticosteroid treatment, such as autoimmune diseases, allergic reactions, and respiratory disorders. Additionally, the rise in healthcare expenditure, coupled with advancements in pharmaceutical technologies, has significantly contributed to the growth of the steroid corticosteroids market. The growing awareness regarding the benefits of corticosteroids among healthcare professionals and patients is also a key factor driving market expansion. Furthermore, the launch of innovative drug formulations and delivery methods is anticipated to create lucrative opportunities for market players in the forecast period.

Growth Factor of the Market

The Steroid Corticosteroids market is experiencing significant growth due to a confluence of factors that enhance its demand across various healthcare sectors. The prevalence of chronic diseases, particularly autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus, has increased, leading to a higher requirement for corticosteroid treatments. Moreover, the rising incidence of allergic reactions and respiratory conditions such as asthma has contributed to the market's growth, as corticosteroids are often prescribed to alleviate inflammation and manage symptoms. Another crucial factor driving the market is the increasing geriatric population, which is more susceptible to diseases requiring corticosteroid therapy. Additionally, ongoing research and development efforts aimed at formulating more effective and safer corticosteroid medications are likely to bolster market growth. Finally, the expansion of distribution channels, including the rise of online pharmacies, has improved accessibility for patients seeking corticosteroid treatments, further enhancing market prospects.

Key Highlights of the Market

• Projected global market size of approximately USD 8.5 billion by 2035.
• Significant CAGR of 5.8% expected from 2025 to 2035.
• Increasing prevalence of chronic conditions driving corticosteroid demand.
• Growing geriatric population more susceptible to corticosteroid-requiring diseases.
• Expanding distribution networks improving accessibility of products.

By Product Type

Prednisone:

Prednisone is one of the most commonly prescribed corticosteroids, primarily used to treat various inflammatory and autoimmune conditions. Its effectiveness in suppressing the immune system makes it a preferred choice for conditions like arthritis and severe allergies. The formulation of prednisone in various strengths and dosage forms, including oral tablets and liquid solutions, enhances its adaptability in treatment protocols. As a result, the demand for prednisone is anticipated to remain strong, driven by its established efficacy and widespread use among healthcare providers. Furthermore, the increasing incidence of chronic diseases will push more patients towards prednisone use, solidifying its presence in the steroid corticosteroids market.

Prednisolone:

Prednisolone, a metabolite of prednisone, has gained popularity in the treatment of similar conditions due to its potent anti-inflammatory properties. This product is often preferred in situations where immediate therapeutic effects are necessary, such as in acute inflammatory responses or severe allergic reactions. Prednisolone is available in various formulations, including eye drops and injectable forms, catering to a diverse range of medical needs. The growing awareness of its benefits among healthcare professionals and the patient population is expected to drive its demand further, making it a compelling segment within the steroid corticosteroids market.

Dexamethasone:

Dexamethasone is a highly effective corticosteroid known for its strong anti-inflammatory and immunosuppressive properties. This corticosteroid is frequently used in the management of severe inflammatory conditions, as well as in chemotherapy regimens to mitigate side effects. The recent global health crises have highlighted the importance of dexamethasone in treating severe COVID-19 cases, resulting in heightened demand and visibility of this drug. Its versatility and potency make it a crucial player in the steroid market, and ongoing research into its uses will likely expand its application further, driving market growth in the coming years.

Hydrocortisone:

Hydrocortisone is a naturally occurring glucocorticoid that is often used to treat conditions such as eczema, allergic reactions, and adrenal insufficiency. Its effectiveness in topical formulations and systemic therapies has made it a staple in corticosteroid treatments. With an increasing incidence of dermatological conditions and the need for effective skin treatments, hydrocortisone's demand is expected to grow steadily. The availability of different delivery methods, including creams, ointments, and injectables, enhances its accessibility and, consequently, its market presence.

Methylprednisolone:

Methylprednisolone is widely used to treat severe inflammatory conditions and allergic responses. Its unique formulation allows for both oral and injectable administration, which is advantageous in clinical settings where rapid intervention is necessary. The introduction of long-acting injectable forms of methylprednisolone has further solidified its position in the market, providing sustained therapeutic effects for patients. As the prevalence of chronic inflammatory diseases rises, the demand for methylprednisolone is anticipated to increase, thereby contributing significantly to the overall steroid corticosteroids market.

By Application

Allergic Reactions:

Corticosteroids are frequently employed in the management of allergic reactions, providing quick relief from symptoms such as inflammation, redness, and itching. The rise in allergic conditions, including hay fever and food allergies, has prompted healthcare providers to rely heavily on corticosteroids for effective management. The need for rapid therapeutic action during acute allergic episodes drives the usage of corticosteroids like dexamethasone and hydrocortisone, making this application segment a substantial contributor to market growth. As awareness around allergy prevalence continues to increase, the application of corticosteroids in this sector is expected to expand significantly.

Inflammation:

Inflammation is a common underlying factor in various health conditions, and corticosteroids are essential in managing inflammatory responses. Their ability to suppress the immune response effectively is particularly valuable in treating diseases like rheumatoid arthritis and inflammatory bowel disease. The growing recognition of chronic inflammatory conditions, coupled with the aging population that is more prone to such ailments, contributes to the increasing demand for corticosteroids as anti-inflammatory agents. This segment's growth is anticipated to accelerate as the global population grapples with the burden of inflammatory disorders.

Asthma:

The use of corticosteroids in asthma management is paramount, particularly in controlling symptoms and preventing exacerbations. Corticosteroids like fluticasone and budesonide are commonly prescribed to patients with moderate to severe asthma. The increasing prevalence of asthma globally, especially among children and young adults, drives the demand for effective corticosteroid treatments. As awareness regarding asthma management improves and the therapeutic options expand, the corticosteroid segment is expected to experience robust growth, offering new avenues for patients to achieve better control over their respiratory health.

Rheumatoid Arthritis:

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and pain. Corticosteroids play a crucial role in managing RA symptoms by mitigating inflammation and suppressing the immune system. The increasing incidence of RA, particularly among the aging population, is a significant driver for the corticosteroids market. As patients seek more effective and immediate relief from RA symptoms, the reliance on corticosteroids is expected to grow. Furthermore, the development of new steroid formulations and delivery methods will likely enhance patient compliance and broaden the scope of treatment options available.

Dermatological Conditions:

Dermatological conditions, ranging from eczema to psoriasis, often require corticosteroid treatments to alleviate symptoms and manage flare-ups. The effectiveness of steroids in topical formulations makes them a first-line treatment for many skin disorders. With the increasing prevalence of skin conditions and heightened awareness regarding their management, the demand for corticosteroids in dermatology is expected to rise. The continuous innovation in formulation technology, such as the development of less potent but effective alternatives, will also drive the growth of this application segment within the steroid corticosteroids market.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a pivotal role in the distribution of corticosteroids, providing essential medications to inpatients and outpatients requiring immediate treatment. With the rise in hospital admissions for chronic inflammatory conditions and allergic reactions, the demand for corticosteroids within hospital settings is on the rise. Furthermore, hospital pharmacies often collaborate with healthcare providers to ensure timely delivery of medications, enhancing patient outcomes. This segment is expected to grow significantly as hospitals expand their capabilities to treat a broader range of conditions effectively.

Retail Pharmacies:

Retail pharmacies serve as a primary source for individuals seeking corticosteroids for outpatient treatment. With the increasing prevalence of chronic conditions, retail pharmacies are witnessing a surge in demand for over-the-counter corticosteroid products. The convenience of access and personalized service offered by retail pharmacies enhances their appeal to patients. Additionally, expansion in the number of retail pharmacy chains and their strategic locations will support the growth of corticosteroids in this distribution channel, making it a vital segment in the market landscape.

Online Pharmacies:

The rise of online pharmacies has transformed the way patients access corticosteroid treatments, providing a convenient alternative for those seeking medications from the comfort of their homes. The COVID-19 pandemic has accelerated the shift towards online shopping for healthcare products, including corticosteroids. The ease of comparing prices and accessing various corticosteroid formulations online is attracting a growing number of consumers. As e-commerce continues to expand, the online pharmacy segment is expected to significantly influence the distribution of corticosteroids in the coming years, catering to the demand for convenient healthcare solutions.

Drug Stores:

Drug stores are an integral part of the distribution ecosystem for corticosteroids, providing convenient access to a variety of prescription and over-the-counter medications. The combination of competitive pricing and immediate availability of corticosteroids makes drug stores a popular choice among patients. The growing awareness and availability of corticosteroid products in drug stores will further bolster their significance in the market. As the demand for corticosteroids continues to rise, drug stores are likely to enhance their inventory and expand their product offerings to meet consumer needs.

Clinics:

Clinics, including specialized medical facilities and outpatient clinics, are increasingly important in the distribution of corticosteroids. Many patients rely on clinics for prescription medications as part of their treatment plans for chronic conditions. The on-site availability of corticosteroids allows healthcare providers to administer medications promptly, ensuring better patient outcomes. As the number of clinics expands and their collaboration with pharmaceutical companies deepens, the demand for corticosteroids in clinical settings is expected to grow, reinforcing their significance in the overall distribution landscape.

By Ingredient Type

Betamethasone:

Betamethasone is a powerful corticosteroid commonly used to treat various inflammatory conditions, including skin disorders and allergic reactions. Its high potency allows for effective symptom management, making it a favored choice among healthcare providers. Betamethasone is available in multiple formulations, including topical creams and injectables, catering to a wide range of medical needs. As the prevalence of dermatological and allergic conditions continues to rise, the demand for betamethasone is expected to grow, solidifying its position in the steroid corticosteroids market.

Triamcinolone:

Triamcinolone is another widely used corticosteroid, often prescribed for its anti-inflammatory effects in conditions such as allergies, arthritis, and skin disorders. Its versatility in various formulations, including nasal sprays and injectable forms, enhances its applicability across different therapeutic areas. The increasing incidence of chronic conditions treated with triamcinolone is expected to drive demand, making it a crucial component of the steroid corticosteroids market. Ongoing research into its efficacy and safety profile will also contribute to its growth potential in the coming years.

Fludrocortisone:

Fludrocortisone is a synthetic corticosteroid primarily used in the treatment of adrenal insufficiency and conditions requiring increased sodium retention. While it is less commonly used than other corticosteroids, its unique properties make it essential for specific patient populations. The growing awareness of adrenal disorders and the importance of proper management will likely enhance the demand for fludrocortisone in the market, contributing to a more comprehensive range of corticosteroid treatments available to patients.

Beclomethasone:

Beclomethasone is primarily used in inhaled formulations for asthma and allergic rhinitis, offering rapid relief from respiratory symptoms. Its effectiveness in managing asthma symptoms has made it a popular choice among healthcare providers. The rising prevalence of asthma globally drives the demand for beclomethasone, as patients seek effective treatment options to control their symptoms. As new inhalation technologies emerge and awareness of asthma management improves, beclomethasone is set to play a significant role in the steroid corticosteroids market.

Clobetasol:

Clobetasol is a highly potent topical corticosteroid used in treating various skin conditions, including psoriasis and eczema. Its strong anti-inflammatory properties enable quick relief from symptoms, making it a first-line treatment for many dermatological conditions. As the prevalence of skin disorders continues to rise, the demand for clobetasol is expected to grow, solidifying its importance in the corticosteroid segment. The advent of more user-friendly formulations and ongoing research on its long-term safety profile will further boost its market presence.

By Region

The regional analysis of the Steroid Corticosteroids market reveals significant variations in demand and growth potential. North America currently dominates the market, accounting for approximately 40% of the global share, driven by the high prevalence of chronic diseases, increased healthcare expenditure, and advanced medical infrastructure. The market in North America is expected to witness a CAGR of around 6.2% during the forecast period, bolstered by ongoing innovations in drug formulations and the rising awareness of corticosteroid therapies. The presence of key players in the region further enhances its market performance, providing a competitive landscape that fosters growth.

Europe follows closely, capturing a significant market share of approximately 30%. The region's growth is fueled by the increasing geriatric population and the rising prevalence of inflammatory diseases. Additionally, favorable healthcare policies and access to advanced treatment options contribute to market expansion in Europe. Meanwhile, the Asia Pacific region shows promising growth potential, with an estimated CAGR of around 7.0% during the forecast period, driven by improving healthcare infrastructure and growing awareness of chronic disease management. Despite currently lower market penetration, the increasing demand for corticosteroids in developing countries is expected to propel growth significantly in this region.

Opportunities

The Steroid Corticosteroids market is poised for significant opportunities driven by ongoing advancements in pharmaceutical research and technology. One of the most promising areas of growth lies in the development of novel corticosteroid formulations that offer enhanced efficacy and safety profiles. As researchers focus on creating drugs that minimize side effects while maximizing therapeutic benefits, new corticosteroid products are likely to emerge in the market, catering to patient needs more effectively. This innovation could open up new therapeutic avenues and expand the applicability of corticosteroids across various medical specialties, creating lucrative opportunities for pharmaceutical companies.

Another avenue for growth in the steroid corticosteroids market lies in the increasing globalization of healthcare and the expansion of online pharmacies. With more patients accessing healthcare products and services via digital platforms, companies have the opportunity to tap into a broader customer base. The rise in e-commerce, coupled with the growing trend of telemedicine, presents a unique market opportunity for corticosteroid manufacturers to reach consumers directly. Additionally, as more healthcare providers adopt telehealth practices, the demand for easily accessible medications, including corticosteroids, will likely increase, further promoting market growth and accessibility.

Threats

Despite the promising growth prospects within the Steroid Corticosteroids market, several threats could impact its development. One major concern is the growing scrutiny surrounding the long-term use of corticosteroids due to potential side effects, including increased risk of infections, weight gain, and osteoporosis. As healthcare providers become more cautious about prescribing corticosteroids, this could lead to a decline in demand for certain products. Furthermore, the increasing emphasis on evidence-based medicine and the potential for alternative therapies may divert healthcare professionals' attention away from corticosteroids, resulting in reduced market penetration and growth.

Another significant restraining factor in the steroid corticosteroids market is the complex regulatory landscape governing drug approvals and safety evaluations. The stringent regulatory requirements imposed by health authorities can prolong the time it takes for new corticosteroid formulations to reach the market, hindering innovation and limiting the availability of new products. Additionally, the need for extensive clinical trials to ensure the safety and efficacy of corticosteroids can increase development costs, posing a financial burden for smaller companies in the sector. These factors collectively create challenges that could restrict the overall growth and competitiveness of the Steroid Corticosteroids market.

Competitor Outlook

• Pfizer Inc.
• GlaxoSmithKline plc
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Sanofi S.A.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.
• Novartis AG
• Roche Holding AG
• Horizon Therapeutics plc
• AstraZeneca plc
• Allergan plc
• Eli Lilly and Company
• Sun Pharmaceutical Industries Ltd.

The competitive landscape of the Steroid Corticosteroids market is characterized by a diverse range of players, from large multinational pharmaceutical companies to smaller biotechnology firms. Major players such as Pfizer Inc., GlaxoSmithKline, and Merck & Co. dominate the market, leveraging their extensive resources and research capabilities to develop innovative corticosteroid products. These companies are actively engaged in research and development efforts to expand their product portfolios and enhance their market presence. In addition to traditional corticosteroids, these companies are increasingly investing in the development of novel delivery systems and formulations to improve patient compliance and treatment outcomes.

Moreover, the competitive dynamics are further shaped by collaborations and partnerships among industry players, academic institutions, and research organizations. Such alliances aim to accelerate drug development processes and foster innovation in corticosteroid therapies. For instance, collaborations between pharmaceutical companies and biotechs often lead to the development of combination therapies that can address multiple aspects of chronic conditions, such as inflammation and immune response. This collaborative approach not only enhances the product offerings in the market but also drives competition among companies to deliver superior therapeutic solutions to patients.

Key companies such as AbbVie Inc. and Sanofi S.A. are focusing on strategic acquisitions and mergers to strengthen their market position. By acquiring smaller firms with innovative product pipelines or technologies, these major players can enhance their expertise and accelerate the development of new corticosteroids. Additionally, they are increasingly adopting digital marketing strategies and e-commerce initiatives to reach consumers directly and build brand loyalty. As the market continues to evolve, maintaining a strong competitive edge will require players to stay ahead of regulatory changes, optimize their supply chains, and effectively communicate the benefits of their corticosteroid products to healthcare professionals and patients alike.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sanofi S.A.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Allergan plc
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 AstraZeneca plc
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Holding AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 GlaxoSmithKline plc
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Eli Lilly and Company
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Horizon Therapeutics plc
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Bristol-Myers Squibb Company
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Steroid Corticosteroids Sales Market, By Application
    • 6.1.1 Allergic Reactions
    • 6.1.2 Inflammation
    • 6.1.3 Asthma
    • 6.1.4 Rheumatoid Arthritis
    • 6.1.5 Dermatological Conditions
  • 6.2 Steroid Corticosteroids Sales Market, By Product Type
    • 6.2.1 Prednisone
    • 6.2.2 Prednisolone
    • 6.2.3 Dexamethasone
    • 6.2.4 Hydrocortisone
    • 6.2.5 Methylprednisolone
  • 6.3 Steroid Corticosteroids Sales Market, By Ingredient Type
    • 6.3.1 Betamethasone
    • 6.3.2 Triamcinolone
    • 6.3.3 Fludrocortisone
    • 6.3.4 Beclomethasone
    • 6.3.5 Clobetasol
  • 6.4 Steroid Corticosteroids Sales Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Drug Stores
    • 6.4.5 Clinics

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Steroid Corticosteroids Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Steroid Corticosteroids Sales market is categorized based on

By Product Type

• Prednisone
• Prednisolone
• Dexamethasone
• Hydrocortisone
• Methylprednisolone

By Application

• Allergic Reactions
• Inflammation
• Asthma
• Rheumatoid Arthritis
• Dermatological Conditions

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Clinics

By Ingredient Type

• Betamethasone
• Triamcinolone
• Fludrocortisone
• Beclomethasone
• Clobetasol

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• GlaxoSmithKline plc
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Sanofi S.A.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.
• Novartis AG
• Roche Holding AG
• Horizon Therapeutics plc
• AstraZeneca plc
• Allergan plc
• Eli Lilly and Company
• Sun Pharmaceutical Industries Ltd.